Atea Pharmaceuticals, Inc.
AVIR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001593899
No open-market purchases or sales by Atea Pharmaceuticals, Inc. insiders were filed in the last 90 days; 124 institutions reported holding it in 13F filings for Q2 2026, worth $276.4M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −2 vs. previous quarter
- 124
- 13F valueReported value at the end of Q2 2026
- $276.4M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding AVIR, Q2 2026
No superinvestor reported holding AVIR at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Atea Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 21, 2026 (view filing) | May 18 | 3 days | Murphy Polly A.Director | PPurchase | +6.10K | $4.17 | +$25.4K | +7.1%92.1K after | Amended |
| Jan 17, 2025 (view filing) | Jan 15-16 | 2 days | Berger Franklin MDirector | PPurchase | +25.0K | $3.26 | +$81.5K | +5.5%476.9K after | Amended2 lots |
| Dec 12, 2024 (view filing) | Dec 10 | 2 days | Berger Franklin MDirector | SSale | −359.6K | $2.85 | −$1.02M | −44.3%451.9K after | |
| Sep 19, 2024 (view filing) | Sep 17-19 | 2 days | Sommadossi Jean-PierrePresident, CEO, and Chairman | SSale | −58.0K | $4.04 | −$234.2K | −1.0%5.87M after | 3 lots10b5-1 |
| Jun 21, 2024 (view filing) | Jun 20 | 1 day | Polsky BruceDirector | SSale | −17.5K | $3.49 | −$61.2K | −21.1%65.6K after | |
| Jun 7, 2024 (view filing) | Jun 5 | 2 days | Sommadossi Jean-PierrePresident, CEO, and Chairman | SSale | −1.01K | $4.00 | −$4.02K | 0.0%5.92M after | 10b5-1 |
| Feb 2, 2024 (view filing) | Feb 1 | 1 day | Corcoran AndreaSee Remarks | SSale | −15.8K | $3.84 | −$60.8K | −2.3%670.2K after | |
| Feb 2, 2024 (view filing) | Feb 1 | 1 day | Sommadossi Jean-PierrePresident, CEO, and Chairman | SSale | −56.9K | $3.85 | −$219.1K | −32.8%116.6K after | 10b5-1 |
| Feb 2, 2024 (view filing) | Feb 1 | 1 day | Horga Maria ArantxaChief Medical Officer | SSale | −15.9K | $3.84 | −$60.9K | −38.2%25.7K after | |
| Feb 2, 2024 (view filing) | Feb 1 | 1 day | Foster WayneEVP, Chief Accounting Officer | SSale | −12.5K | $3.84 | −$47.9K | −37.4%20.9K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Atea Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 12,004,064 | $55.8M | 0.00% | +53,292+0.4% | Added |
| BlackRock, Inc. | 8,720,077 | $40.5M | 0.00% | +284,640+3.4% | Added |
| BML Capital Management, LLC | 6,952,330 | $32.3M | 18.46% | −106,327−1.5% | Reduced |
| Tang Capital Management LLC | 4,814,700 | $22.4M | 1.02% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 2,964,862 | $13.8M | 0.00% | −281,262−8.7% | Reduced |
| Bain Capital Life Sciences Investors, LLC | 2,075,639 | $9.65M | 0.57% | −284,999−12.1% | Reduced |
| Acadian Asset Management LLC | 2,035,192 | $9.46M | 0.01% | +452,375+28.6% | Added |
| Geode Capital Management, LLC | 1,958,435 | $9.11M | 0.00% | +210,729+12.1% | Added |
| State Street Corp | 1,652,399 | $7.68M | 0.00% | −42,236−2.5% | Reduced |
| Two Sigma Investments, LP | 1,506,697 | $7.01M | 0.01% | −357,467−19.2% | Reduced |